Pfizer · NSE: PFIZER · BSE: 500680
Q3 FY23 results · Oct–Dec 2022
Pfizer reported revenue from operations of ₹621.75 crore (down 8.0% from Q3 FY22) and net profit of ₹150.66 crore (up 4.7% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 621.75 | 675.90 | −8.0% | 637.47 | −2.5% |
| Other income | 27.41 | 18.26 | +50.1% | 24.24 | +13.1% |
| Total income | 649.16 | 694.16 | −6.5% | 661.71 | −1.9% |
| Profit before tax | 200.68 | 184.09 | +9.0% | 415.22 | −51.7% |
| Net profit for the period | 150.66 | 143.91 | +4.7% | 311.07 | −51.6% |
| EPS, basic (₹) | 32.93 | 31.46 | +4.7% | 67.99 | −51.6% |
| Net margin (%) | 24.2 | 21.3 | 48.8 |
Standalone
- Filed with BSE
- 09 Feb 2023, 17:43 IST
- Board meeting
- 09 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE